phosphodiesterase inhibitor

(redirected from PDE4 inhibitor)

phosphodiesterase inhibitor

Abbreviation: PDE inhibitor
Any agent that blocks phosphodiesterase, inhibiting the production of second messengers within cells, such as cyclic adenosine monophosphate or cyclic glucose monophosphate. Drugs that inhibit PDE include sildenafil, an agent used to treat erectile dysfunction, and other agents used as positive inotropes and vasodilators in heart failure.
See also: inhibitor

phosphodiesterase inhibitor

positive inotrope (e.g. enoximone [Perfan]); see inotrope

inhibitor

1. any substance that interferes with a chemical reaction, growth or other biological activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.

coagulation i's
clotting factors.
fibrinolytic i's
clotting factors.
phosphodiesterase inhibitor
inhibits phosphodiesterase, which in turn inactivates cyclic adenosine monophosphate. The effect of the inhibitor is to increase the heart muscle content of cAMP.
reversible i's
pharmaceutical inhibitors which have only a temporary effect, e.g. the cholinesterase inhibitors neostigmine, physostigmine.
References in periodicals archive ?
TM)](aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
Additionally, AstraZeneca will own the development and commercial rights in the US and Canada Daliresp (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD.
Apremilast is an oral PDE4 inhibitor that modulates cyclic AMP metabolism and in inflammatory cells results in decreased production of pro-inflammatory mediators, such as TNF, IL17, and IL23, and increased production of anti-inflammatory mediators, such as IL10.
The PDE4 inhibitor, which was discovered by Tanabe Seiyaku, has a property of inhibiting the activity of inflammatory cells.
The anti-inflammatory activity of CHF 6001 has been proven in vitro and in several animal models of airway inflammation, showing higher potency than the marketed oral PDE4 inhibitor (roflumilast) and more targeted anti-inflammatory effects than corticosteroids in COPD models.
Novel therapies aimed at alternative targets such as interleukin 12/23 (IL-12/23), interleukin-17 (IL-17), interleukin-6 (IL-6), phosphodiesterase type 4 (PDE4) and janus kinase (JAK) are in active development, with a PDE4 inhibitor and an anti-IL-12/23 closest to approval for PsA.
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
AstraZeneca owns the development and commercial rights in the US and Canada to TudorzaTM PressairTM (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), and to DalirespA (roflumilast), the only once-daily oral PDE4 inhibitor currently on the market for COPD, in the US.
Otezla is the first PDE4 inhibitor approved for the treatment of plaque psoriasis.
Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders
The Oral options- JAK inhibitors led by PFE's Tofacitinib and CELG's PDE4 inhibitor, Apremilast.
From 2007 to 2013 he was EVP Head of R&D at Nycomed Pharma Pvt Limited where he led the development and approval of Daxas, the PDE4 inhibitor used to prevent COPD exacerbations.